Lupin Ltd.
NSE: LUPIN · Pharmaceuticals
Snapshot
Unlock Lupin Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Lupin Limited is a global pharmaceutical company that develops, manufactures, and markets a diverse portfolio of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. The company operates across multiple therapeutic areas, including cardiovascular, respiratory, and anti-infective segments, with a significant international presence.
Business Model
The company generates revenue through the sale of pharmaceutical products across global markets, supported by an extensive network of laboratories and collection centres. Its business model integrates drug discovery, clinical research, and the commercialisation of specialty and biosimilar products.
- Laboratories:18
- Collection Centres:280
- Pick-up Points:450
Growth Outlook
Growth is driven by the expansion of its specialty products portfolio and ongoing drug discovery programmes in oncology, immunology, and metabolic disorders. The company continues to leverage its global footprint to capture market share in both developed and emerging pharmaceutical markets.
Key Risks
- Regulatory Compliance. The company faces stringent oversight from global health authorities, where any failure to meet manufacturing standards could lead to import bans or product recalls.
- Pricing Pressure. Intense competition in the generic drug market and government-mandated price controls in key regions may compress profit margins.
- R&D Uncertainty. The long-term success of the company depends on the high-risk, high-cost drug discovery and development pipeline, which may not always yield commercially viable products.
- Currency Volatility. As a global entity with operations in multiple countries, the company is exposed to fluctuations in foreign exchange rates that can impact reported earnings.
Start your research today
Unlock AI insights, financials, peers and live data on Lupin Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹29,967 Cr
TTM · consolidated
NET PROFIT
₹5,551 Cr
TTM · consolidated
EPS
₹121.01
TTM · consolidated
RETURN ON EQUITY
28.0%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
34.5%
TTM · consolidated
P/E
17.4x
Q1 FY27 · consolidated
EV/EBITDA
9.8x
Q1 FY27 · consolidated
EBITDA MARGIN
33.4%
TTM · consolidated
NET PROFIT MARGIN
17.1%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.3x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Lupin Ltd.LUPIN | ₹96,476 Cr | 17.44 | 9.81 | 28.2% | 33.4% | 28.0% | 34.5% | +8.8% |
Cipla Ltd.CIPLA | ₹1.12L Cr | 33.18 | 18.12 | 1.8% | 21.6% | 10.2% | 13.6% | -12.2% |
Laurus Labs Ltd.LAURUSLABS | ₹99,334 Cr | 90.82 | 48.68 | 22.6% | 28.7% | 22.3% | 25.3% | +110.5% |
Mankind Pharma Ltd.MANKIND | ₹96,141 Cr | 47.04 | 24.59 | 14.4% | 28.2% | 13.5% | 14.3% | -9.4% |
Dr. Reddy's Laboratories Ltd.DRREDDY | ₹96,070 Cr | 29.75 | 15.36 | -0.9% | 19.8% | 8.9% | 11.4% | -8.1% |
Aurobindo Pharma Ltd.AUROPHARMA | ₹95,116 Cr | 25.83 | 12.30 | 9.1% | 22.3% | 10.5% | 15.4% | +59.6% |
As of Q1 FY27
Financials
Lupin Ltd.
NSE: LUPIN · Pharmaceuticals
Snapshot
Unlock Lupin Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Lupin Limited is a global pharmaceutical company that develops, manufactures, and markets a diverse portfolio of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. The company operates across multiple therapeutic areas, including cardiovascular, respiratory, and anti-infective segments, with a significant international presence.
Business Model
The company generates revenue through the sale of pharmaceutical products across global markets, supported by an extensive network of laboratories and collection centres. Its business model integrates drug discovery, clinical research, and the commercialisation of specialty and biosimilar products.
- Laboratories:18
- Collection Centres:280
- Pick-up Points:450
Growth Outlook
Growth is driven by the expansion of its specialty products portfolio and ongoing drug discovery programmes in oncology, immunology, and metabolic disorders. The company continues to leverage its global footprint to capture market share in both developed and emerging pharmaceutical markets.
Key Risks
- Regulatory Compliance. The company faces stringent oversight from global health authorities, where any failure to meet manufacturing standards could lead to import bans or product recalls.
- Pricing Pressure. Intense competition in the generic drug market and government-mandated price controls in key regions may compress profit margins.
- R&D Uncertainty. The long-term success of the company depends on the high-risk, high-cost drug discovery and development pipeline, which may not always yield commercially viable products.
- Currency Volatility. As a global entity with operations in multiple countries, the company is exposed to fluctuations in foreign exchange rates that can impact reported earnings.
Start your research today
Unlock AI insights, financials, peers and live data on Lupin Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹29,967 Cr
TTM · consolidated
NET PROFIT
₹5,551 Cr
TTM · consolidated
EPS
₹121.01
TTM · consolidated
RETURN ON EQUITY
28.0%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
34.5%
TTM · consolidated
P/E
17.4x
Q1 FY27 · consolidated
EV/EBITDA
9.8x
Q1 FY27 · consolidated
EBITDA MARGIN
33.4%
TTM · consolidated
NET PROFIT MARGIN
17.1%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.3x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27